author-photo

J Hoog

University of Washington

15

Papers

34

Citations

Citation Trend

Filter By

Papers (11) Sort By

Journal Conference Others

Abstract P4-04-01: Loss of mismatch repair predicts resistance to endocrine therapy and sensitivity to CDK4/6 inhibitors in ER+ breast cancer

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Abstract P2-09-16: Tumor infiltrating lymphocytes (TILs) as a biomarker for resistance to palbociclib (Pal) in the NeoPalAna trial

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract P2-09-19: Genomic biomarker for resistance to palbociclib in the NeoPalAna trial

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract P5-04-02: Serum thymidine kinase 1 activity as a pharmacodynamics marker of cyclin-dependent kinase 4/6 inhibition in patients with early stage breast cancer receiving neoadjuvant palbociclib

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PD2-03: Recurrent functionally diverse in-frameESR1gene fusions drive endocrine resistance in breast cancer

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract P5-13-04: A phase II neoadjuvant trial of MK-2206, an AKT inhibitor, in combination with anastrozole for clinical stage 2 or 3 PIK3CA mutant estrogen receptor positive HER2 negative (ER+HER2-) breast cancer (BC)

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Abstract S6-05: A phase II trial of neoadjuvant palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with anastrozole for clinical stage 2 or 3 estrogen receptor positive HER2 negative (ER+HER2-) breast cancer (BC)

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (12)
Abstract LB-265: Patient-derived xenografts from advanced luminal-type breast cancer: insights into endocrine therapy resistance.

2013 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract LB-87: Analysis of luminal-type breast cancer by massively parallel sequencing

2011 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
P1-06-13: An Amplicon-Driven Aromatase Inhibitor Response (ADAIR) Signature Provides an Orthogonal Risk Classifier for ER+ Breast Cancer.

2011 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)